Sage Therapeutics (SAGE) PT Raised to $259 at RBC Capital Following PPD Survey
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams raised the price target on Sage Therapeutics (NASDAQ: SAGE) to $259.00 (from $255.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
